For the identification of breast cancer patients who might benefit from targeted therapy with specific PIK3CA inhibitors, locally deployable highly sensitive, and specific PIK3CA mutation testing that covers all actionable mutations is required. Here, PIK3CA is linked to breast carcinoma.